Afzanna 40mg Tablet

Uses of Afzanna 40mg Tablet

Afzanna 40mg Tablet is indicated to treat the following conditions:

  • Non-small cell lung cancer (NSCLC)

Introduction Of Afzanna 40mg Tablet

Afzanna 40mg Tablet is an anticancer medicine containing Afatinib dimaleate as an active ingredient. It is used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) genes and patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy. Cancer is a disorder in which cells multiply in an abnormal and uncontrolled manner.

Afzanna 40mg Tablet can delay disease progression and improve overall survival, it can also help patients maintain a better quality of life for a longer period of time. This includes improved physical functioning, reduced pain, and better mental and emotional health. Tell your doctor if you are wearing contact lenses or breastfeeding before taking this medication.

Therapeutic Effects of Afzanna 40mg Tablet

The therapeutic effect of Afzanna  Tablet is primarily related to its ability to inhibit the activity of certain proteins in cancer cells, specifically the epidermal growth factor receptor (EGFR) family of proteins. These proteins play a key role in promoting the growth and spread of cancer cells, and by inhibiting their activity, it can help to slow or stop the progression of cancer.


Interaction of Afzanna 40mg Tablet with other drugs

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products.

More Information about Afzanna 40mg Tablet

  • Afzanna 40mg Tablet should be stored at room temperature, between 40°C to 25°C (68°F to 77°F).
  • Protected from light.
  • Keep it in its original packaging until it is ready to be used.
  • Keep out of the reach of children and pets.
  • Should be disposed of properly.

How to consume Afzanna 40mg Tablet

Afzanna 40mg Tablet is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect how the medication is absorbed and decrease its effectiveness.


Safety Advices for Afzanna 40mg Tablet

 

Pregnancy

Consult your doctor

Afzanna  Tablet is unsafe during pregnancy as it can cause fetal harm. It is recommended to avoid this medication during pregnancy.

 

Breast Feeding

Consult your doctor

It is unknown, whether Afzanna  Tablet is excreted in human milk or not, and the potential risks to a nursing infant are unknown. So nursing women should consult a healthcare provider before taking it.

 

Lungs

Consult your doctor

Afzanna Tablet is primarily used to treat non-small cell lung cancer (NSCLC). Patients should consult healthcare providers if they have any other lung disease before taking it.

 

Liver

Consult your doctor

Afzanna 40mg Tablet is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases.

Alcohol

Unsafe

It is recommended to avoid consuming alcohol while taking Afzanna  Tablet, as alcohol can increase the risk of certain side effects associated with the medication, such as stomach ulcers or gastrointestinal bleeding.

 

Driving

Consult your doctor

Patients receiving Afzanna 40mg Tablet should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient’s ability to drive or operate machinery safely.


Side Effects of Afzanna 40mg Tablet

Serious:

  • Interstitial lung disease
  • Severe diarrhea or dehydration
  • Liver problems

Common:

  • Diarrhea
  • Mouth sores
  • Acne or skin rash

Brand

Celon Laboratories LTD

Reviews

There are no reviews yet.

Be the first to review “Afzanna 40mg Tablet”

Your email address will not be published. Required fields are marked *

Top